GE HealthCare Leverages a Century of Innovation to Define Radiology’s Future at RSNA 2025

• The company will showcase a wave of transformative innovations designed to address the most pressing challenges in healthcare, spanning the care journey across smart devices and drugs throughout disease states enabled by cloud and AI solutions.
• GE HealthCare has invested more than $3 billion in research and development since 2022, fueling an innovation renaissance across disease states to advance precision care.

CHICAGO — At this year’s Radiological Society of North America (RSNA) 2025 Annual Meeting, GE HealthCare (Nasdaq: GEHC) will unveil a broad portfolio of new technologies rooted in its century‑long heritage of marrying medicine with engineering. From the early days of x‑ray tubes to today’s AI‑driven, cloud‑first solutions, the company is positioning itself at the forefront of precision health.

Solving industry challenges

Radiology departments worldwide are under mounting pressure: a growing shortage of qualified staff, escalating demand for imaging services, rapid technology cycles, and the imperative to improve operational efficiency. GE HealthCare is responding with cloud‑based and AI‑enabled platforms that turn raw imaging data into actionable insights, accelerate diagnosis, and help hospitals streamline workflows.

At RSNA 2025 the firm will demonstrate more than 40 innovations that combine cutting‑edge hardware with advanced computational and AI capabilities. Highlights include AI‑augmented imaging systems that reduce cognitive load, automated routine‑task pipelines, and structured reporting tools that improve data consistency across the enterprise.

“Our goal is to deliver technologies that empower clinicians, drive efficiencies, and improve patient outcomes across multiple care pathways,” said Peter Arduini, CEO of GE HealthCare. “We start by listening to our customers, then work backwards to develop differentiated solutions for today and tomorrow.”

Key products driving GE HealthCare’s innovation renaissance

Since 2022, GE HealthCare has poured more than $3 billion into R&D, resulting in a pipeline that spans imaging hardware, radiopharmaceuticals, and cloud‑first AI solutions. The following products will be highlighted at RSNA:

• Photonova™ Spectra (510(k) pending with the U.S. FDA) – A photon‑counting CT system built on the company’s proprietary Deep Silicon detector. The system delivers ultra‑high‑definition (UHD) spectral and spatial resolution, capturing up to 50 times more data than conventional CT scanners. This data density enables advanced reconstruction algorithms that improve material discrimination and support faster, more precise clinical decision‑making.
• Next‑generation SIGNA MRI technology (510(k) pending) – Includes:
  • SIGNA™ Bolt – A high‑field, wide‑bore 3.0 T MRI that pairs ultra‑high gradient performance with an intelligent digital RF architecture, delivering precision imaging while consuming markedly less energy.
  • SIGNA™ Sprint with Freelium™ – A low‑helium design that uses less than 1 % of the helium required by conventional magnets, reducing operating costs and environmental impact without compromising image quality.
  • SIGNA™ One – An AI‑powered workflow platform that simplifies protocol selection and automates routine tasks, improving throughput and diagnostic confidence.
• Pristina™ Recon DL – The first 3‑D mammography reconstruction solution that blends deep‑learning algorithms with iterative reconstruction. The technology delivers high‑quality digital breast tomosynthesis (DBT) images at a lower radiation dose, enhancing early cancer detection while improving patient comfort.
• Vivid™ Pioneer – An adaptive cardiovascular ultrasound platform featuring one‑click optimization, AI‑driven automation, a lightweight battery‑operated design, and an intuitive user interface. The system is engineered for high‑resolution imaging in fast‑paced clinical environments.
• Flyrcado™ (flurpiridaz F 18) injection – An FDA‑approved PET myocardial perfusion imaging (MPI) agent for adult patients with known or suspected coronary artery disease. The tracer offers longer half‑life and higher diagnostic efficacy than traditional SPECT, facilitating exercise‑stress PET workflows and expanding access to advanced cardiac imaging.
• Definium Pace Select ET – A floor‑mounted digital X‑ray system that leverages AI for automated patient positioning and consistent image quality. Designed for high‑throughput settings, the solution reduces manual steps, lowers technologist fatigue, and improves overall image acquisition efficiency.

AI and cloud‑enabled workflow efficiencies

• Genesis™ Radiology Workspace – A zero‑footprint, cloud‑first diagnostic viewer that unifies image archiving, workflow management, and AI applications. The platform aims to accelerate case review, enable remote access, and standardize the user experience across sites.
• 100 FDA‑authorized AI‑enabled solutions – GE HealthCare leads the industry in AI device clearances, providing tools that automate lesion detection, quantify disease burden, and suggest optimized imaging protocols. This breadth of AI offerings supports faster, more accurate decision‑making and broadens access to high‑quality care.

“For more than 125 years, GE HealthCare has pioneered technologies that transform patient care. While we honor our legacy, we remain focused on a future where care is more personalized, connected, and intelligent,” said Roland Rott, CEO and President of Imaging at GE HealthCare. “Our new innovations empower clinicians and push the boundaries of what’s possible in health care.”

A legacy rooted in discovery

GE HealthCare’s influence spans the entire history of medical imaging. The company introduced the first full‑body CT scanner, commercialized magnetic resonance imaging, and launched the pocket‑size Vscan handheld ultrasound in 2010. Recent milestones include:

• Sixty years of mammography – From the first dedicated X‑ray unit in 1965 to today’s AI‑enhanced 3‑D systems, GE continues to drive early‑detection technologies for women’s health.
• Twenty‑five years of PET/CT – Since the introduction of the world’s first commercially available PET/CT system in 2001, the technology has become central to oncology imaging, enabling precise staging and treatment monitoring.
• Flyrcado – The first PET molecular imaging agent for coronary artery disease, representing a paradigm shift in nuclear cardiology.

Strategic collaborations driving innovation

Beyond internal R&D, GE HealthCare accelerates growth through strategic acquisitions and partnerships:

• MIM Software – Enhances advanced imaging analytics, visualization, and workflow solutions.
• Spectronic Medical – Provides radiation oncology planning tools that integrate with GE’s imaging ecosystem.
• icometrix – Expands AI‑enabled precision imaging for neurology, offering automated brain MRI assessment and disease‑progression monitoring.

For more information on GE HealthCare’s RSNA showcase, visit booth 7334 or consult the company’s press kit.

Important safety information – Flyrcado™ (flurpiridaz F 18) injection

Indications and usage: Flyrcado is indicated for PET myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease to evaluate myocardial ischemia and infarction.

Contraindications: None.

Warnings and precautions:

• Stress testing – Patients may experience serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, or seizure. Stress testing should be performed where cardiac resuscitation equipment and trained staff are available.
• Radiation risk – Flyrcado contributes to cumulative radiation exposure, which is associated with an increased long‑term cancer risk. Proper handling and patient hydration/voiding protocols are recommended.

Adverse reactions (≥ 2 % incidence): dyspnea, headache, angina, chest pain, fatigue, ST‑segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.

Use in specific populations:

• Pregnancy – No data on fetal risk; discuss potential radiation exposure with patients.
• Lactation – Discontinue breastfeeding and discard breast milk for at least 8 hours after administration.
• Pediatric use – Safety and effectiveness have not been established.

For full prescribing information and detailed safety data, refer to the product’s FDA label.

About GE HealthCare Technologies Inc.

GE HealthCare is a global leader in medical technology, pharmaceutical diagnostics, and integrated, cloud‑first AI solutions. The company’s portfolio spans imaging, advanced visualization, patient care solutions, and pharmaceutical diagnostics, supporting the full continuum of care from screening to therapy and monitoring. With annual revenue of $19.7 billion and a workforce of roughly 53,000 employees, GE HealthCare is committed to delivering personalized, connected, and compassionate health care worldwide.